2003

Bush blocks deal allowing cheap drugs

1 April 2003. Related: Treatment access.

Roche to sell nelfinavir, saquinavir at cost to least-developed nations

1 April 2003. Related: Treatment access.

South Africa appoints another dissident

1 April 2003. Related: Treatment access.

US implementation of large-scale smallpox vaccination plan has special implications for people with HIV

1 April 2003. Related: Basic science and immunology.

UK HIV new cases at record high

1 April 2003. Related: Other news.

Trizivir-only arm closed in PI-sparing, naïve therapy trial

1 April 2003. Related: Antiretrovirals, Other news.

Reduced testosterone levels in HIV-positive women

1 April 2003. Related: Women's health, Lipodystrophy and metabolic complications, Other news.

Fosamprenavir expanded access in UK

1 April 2003. Related: Antiretrovirals, Other news.

European approval of adefovir for hepatitis B

1 April 2003. Related: Hepatitis coinfection, Other news.

European activists highlight importance of gender based research: women experience HIV differently

1 April 2003. Related: Women's health, Other news.

Roche prices enfuvirtide (T-20) at €18,980 a year – making it the most expensive HIV drug yet

1 April 2003. Related: Antiretrovirals.

European positive opinion for tenofovir for first-line therapy

1 April 2003. Related: Antiretrovirals.

Vaxgen announces disappointing results from first large international vaccine trial

1 April 2003. Related: Vaccines and microbicides.

GMHC criticises Vaxgen for obfuscation of trial results of its AIDS vaccine

1 April 2003. Related: Vaccines and microbicides.

Antibiotic-resistant skin infections spreading among gay men, also in prisons

1 April 2003. Related: Other news.

Further Glasgow and Retrovirus reports

1 April 2003. Related: On the web.

Medscape: articles in full from AIDS, Journal AIDS etc

1 April 2003. Related: On the web.

Contents of newsletters now online: Beta, amfAR Insider, PRN Notebook, GMHC Treatment Issues

1 April 2003. Related: On the web.

New HIVinSite Knowledge Base chapters; new website for information on herbs and supplements

1 April 2003. Related: On the web.

HHS Clinical Guide on Palliative Care of HIV/AIDS Patients

1 April 2003. Related: On the web.

Volume 4 Number 3 April 2003 PDF

1 April 2003. Related: PDFs.

Volume 4 Number 2 March 2003

1 March 2003. Related: Editorial.

10th Conference on Retroviruses and Opportunistic Infections, 10-14 February 2003, Boston, USA

1 March 2003. Related: Conference reports.

Bush plans $15 billion budget to treat two million people and prevent seven million infections in 14 countries – but meets criticism from activists

1 March 2003. Related: Treatment access.

The World Health Organisation must continue its work on access to medicines in developing countries

1 March 2003. Related: Treatment access.

Dr Jong-Wook Lee nominated to be WHO director-general

1 March 2003. Related: Treatment access.

AAI Pharma access programme providing treatment for 36,000 people in Africa

1 March 2003. Related: Treatment access.

Pharmacia to launch pilot programme for expanding access to medicines in the poorest countries

1 March 2003. Related: Treatment access.

Heineken to offer antirerotviral drug coverage to African workforce

1 March 2003. Related: Treatment access.

Five pharmaceutical companies to halve antiretroviral drug prices for central America

1 March 2003. Related: Treatment access.

Patent law overrides would not expand access to drugs for low-income nations, opinion piece says

1 March 2003. Related: Treatment access.

Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne

1 March 2003. Related: Antiretrovirals.

Subtle decreases in stavudine (d4t, Zerit) phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine (AZT, Retrovir)-experienced patients

1 March 2003. Related: Drug resistance.

Medical care providers have very limited knowledge of resistance-associated drug mutations

1 March 2003. Related: Drug resistance.

Inhibitory quotient useful as indicator of effective protease inhibitor therapy

1 March 2003. Related: Drug resistance.

30-year study links vitamin A to risk of fracture in humans

1 March 2003. Related: Lipodystrophy and metabolic complications.

Bone turnover elevated in HIV-positive patients and linked to duration of HAART

1 March 2003. Related: Lipodystrophy and metabolic complications.

Efavirenz effects worse than reported, study says

1 March 2003. Related: Side effects.

Protease inhibitors and cardiovascular outcomes in patients with HIV-1

1 March 2003. Related: Side effects, Lipodystrophy and metabolic complications.

HIV protease inhibitors promote atherosclerosis independent of dyslipidemia

1 March 2003. Related: Side effects, Lipodystrophy and metabolic complications.

HAART-associated hyperlipidaemia linked to low risk for cardiovascular disease (CVD)

1 March 2003. Related: Lipodystrophy and metabolic complications.

Patient on human growth hormone develops tumours with growth hormone receptors

1 March 2003. Related: Lipodystrophy and metabolic complications.

Review of trials shows testosterone increases lean body mass, and is most effective when given intramuscularly

1 March 2003. Related: Lipodystrophy and metabolic complications.

Antiretroviral treatment increases adult thymic volume

1 March 2003. Related: Basic science and immunology.

Rituximab and chemotherapy is highly effective in patients with CD20-positive non-Hodgkin’s lymphoma and HIV

1 March 2003. Related: Cancer and HIV.

Lung cancer in HIV positive HAART-users

1 March 2003. Related: Cancer and HIV.

Functional MRI can find brain abnormalities in asymptomatic patients

1 March 2003. Related: Coinfections and complications.

Hepatitis C virus viraemia in HIV-positive individuals with negative HCV antibody tests

1 March 2003. Related: Hepatitis coinfection.

Roche’s Copegus (ribaviran) available in UK for use in the treatment of Hepatitis C

1 March 2003. Related: Hepatitis coinfection.

PEG-Intron plus ribavirin in non-responders and relapsers

1 March 2003. Related: Hepatitis coinfection.

Dangers of HIV/hepatitis B coinfection

1 March 2003. Related: Hepatitis coinfection.

SILCAAT IL-2 study saved as investigators take over responsibility and Chiron agrees to continue funding

1 March 2003. Related: Other news.

Drug industry contributions influence clinical research, JAMA study says

1 March 2003. Related: Other news.

Accuracy of pharmaceutical advertisements in medical journals

1 March 2003. Related: Other news.

Lack of new drugs is reaching crisis point, says review

1 March 2003. Related: Other news.